Anavex Life Sciences Presents New Data Of Blarcamesine At AD/PD 2026 Conference; Data Show Brain-Volume Preservation Correlates With Patient Outcomes

Anavex Life Sciences Corp. presented new data on its drug blarcamesine at the AD/PD 2026 Conference, highlighting a significant time savings of 77.4 weeks (17.8 months) for patients compared to the ADNI1 control group after 144 weeks of treatment. The oral presentation emphasized the convenience of blarcamesine for patients and families, drawing from the Phase IIb/III clinical program. Anavex focuses on developing treatments for Alzheimer's and other CNS disorders.